The impact of nimodipine combined with Ginkgo biloba extract on cognitive function and ADL scores in patients with Parkinson's disease: A retrospective study
- PMID: 39029001
- PMCID: PMC11398803
- DOI: 10.1097/MD.0000000000038720
The impact of nimodipine combined with Ginkgo biloba extract on cognitive function and ADL scores in patients with Parkinson's disease: A retrospective study
Abstract
This study aims to explore the value of nimodipine combined with Ginkgo biloba extract in improving cognitive function and daily living abilities in patients with Parkinson's disease. Clinical data from 551 patients with Parkinson's disease admitted to the Neurology Department of the Affiliated Hospital of Beihua University from January 2022 to December 2022 were retrospectively collected. Cognitive function and daily living abilities were assessed in patients before treatment, and a reevaluation was conducted after 12 weeks of medication. Patients treated solely with nimodipine were categorized into the monotherapy group, while patients treated with nimodipine combined with Ginkgo biloba extract were included in the combination group. After 1:1 propensity score matching, a total of 83 pairs of patients were matched, and differences in relevant indicators between the 2 groups were compared. The total effective rate of treatment in the combination group was 90.36%, which was higher than the control group at 72.29% (P < .05). However, after treatment, the observation group showed higher Mini-Mental State Examination and activities of daily living scores compared to the control group (P < .05). The combined treatment of nimodipine and Ginkgo biloba extract in patients with Parkinson's disease has a significant effect and can effectively improve cognitive function and enhance daily living abilities.
Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures
Similar articles
-
Effectiveness and Safety Profile of Ginkgo biloba Standardized Extract (EGb761®) in Patients with Amnestic Mild Cognitive Impairment.CNS Neurol Disord Drug Targets. 2021;20(4):378-384. doi: 10.2174/1871527320666210208125524. CNS Neurol Disord Drug Targets. 2021. PMID: 33557741 Clinical Trial.
-
Effects of oxiracetam combined with ginkgo biloba extract in the treatment of acute intracerebral hemorrhage: A clinical study.Brain Behav. 2020 Aug;10(8):e01661. doi: 10.1002/brb3.1661. Epub 2020 Jun 12. Brain Behav. 2020. PMID: 32533644 Free PMC article.
-
An examination of the efficacy of Ginkgo biloba extract EGb761 on the neuropsychologic functioning of cognitively intact older adults.J Altern Complement Med. 2000 Jun;6(3):219-29. doi: 10.1089/acm.2000.6.219. J Altern Complement Med. 2000. PMID: 10890330 Clinical Trial.
-
Ginkgo Biloba for Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Curr Top Med Chem. 2016;16(5):520-8. doi: 10.2174/1568026615666150813143520. Curr Top Med Chem. 2016. PMID: 26268332 Review.
-
Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis.J Alzheimers Dis. 2015;43(2):589-603. doi: 10.3233/JAD-140837. J Alzheimers Dis. 2015. PMID: 25114079 Review.
References
-
- Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;77:874–874. - PubMed
-
- Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013;62:132–44. - PubMed
-
- Van Den Eeden SK, et al. . Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157:1015–22. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical